Complexa Names William Leong, Vice President of Chemistry, Manufacturing and Controls
BERWYN, PA, July 26, 2018 – Complexa Inc. today announced the appointment of William Leong, PhD, as Vice President of Chemistry, Manufacturing and Controls (CMC). Dr. Leong formerly served as Executive Director, Head of CMC for Newron Pharmaceuticals, where he led strategies to advance the company’s small and large molecule candidates from pre-clinical to commercial manufacturing.
“William is a great addition to our management team as he brings a wealth of CMC experience with a proven track record of success moving candidates from the laboratory to market,” said Francisco Salva, President and Chief Executive Officer of Complexa. “With our lead product candidate, CXA-10, in Phase 2 development, we look to William’s leadership to help us navigate regulatory and manufacturing processes as we progress through the clinic, with the goal of offering patients with life-threatening fibrotic and inflammatory diseases a potential new treatment option.”
In his role at Complexa, Dr. Leong will drive all CMC operations with responsibility for leading formulation development, process development, analytical science and supply chain activities. He will also manage all collaborations with experts, from academia to contract manufacturing organizations.
During his tenure with Newron Pharmaceuticals, Dr. Leong executed integrated strategies for drug substance, product formulation, analytical certification, medical device, clinical supply chain, quality assurance and global regulatory submissions. He also led the marketing approvals for Xadago (Safinamide) in the United States, the European Union and Switzerland. As Senior Director, Head of Process Chemistry at Celgene Corporation, he directed all operations of the Process Chemistry Department, most notably strategic development for rapid in-house manufacture of new chemical entities. Dr. Leong began his career as a scientist at Schering-Plough Research Institute, where he also held roles of increasing responsibility within the company.
Dr. Leong holds a Bachelor of Science degree in Chemistry from the University of San Francisco and a Doctor of Philosophy from the University of California, Davis. He completed a Post-doctoral Research Fellowship at Iowa State University, Ames. He has authored several publications and holds manufacturing patents in the United States and Europe.
Complexa Inc. is a patient-focused, science-driven, clinical stage biopharmaceutical company developing a novel class of compounds, nitrated fatty acids (NFAs), for the safe and effective treatment of debilitating fibrotic and inflammatory diseases. NFAs have demonstrated broad potential to be effective therapeutic agents in multiple disease indications in which oxidative stress, inflammation, fibrosis and/or direct tissue toxicity play significant roles. This class of molecules has the potential to be disease-modifying in many disorders, given NFAs’ broad activity. An experienced consortium of investors, including Andera Partners, HBM Healthcare Investments, JAFCO, New Enterprise Associates (NEA) and Pfizer Venture Investments have committed funding to advance a platform of NFA agents across multiple orphan disease indications. Complexa’s lead candidate, CXA-10, is currently in Phase 2 development for focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH). For more information, visit www.complexarx.com.
# # #
Sam Brown Inc.